Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.69 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | TYMP | P19971 | 3/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | DPP4 | P27487 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.63 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.63 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.63 |
| ▸ | GAPDH | P04406 | 1/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.63 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.63 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.63 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.63 |
| ▸ | STAT6 | P42226 | 1/20 | 0.63 |
| ▸ | PI4KA | P42356 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Inosine SCHEMBL13062153 | 1.00 | PAX8 (0.69) | PAX8P2RX3HPGDTYMPMAPK1 | |
| Inosine SCHEMBL13320592 | 1.00 | PAX8 (0.69) | PAX8P2RX3HPGDTYMPMAPK1 | |
| Inosine SCHEMBL6748953 | 1.00 | PAX8 (0.69) | PAX8P2RX3HPGDTYMPMAPK1 | |
| Inosine SCHEMBL18249508 | 1.00 | PAX8 (0.69) | PAX8P2RX3HPGDTYMPMAPK1 | |
| Inosine SCHEMBL12964365 | 1.00 | PAX8 (0.69) | PAX8P2RX3HPGDTYMPMAPK1 | |
| Inosine SCHEMBL1738548 | 1.00 | PAX8 (0.69) | PAX8P2RX3HPGDTYMPMAPK1 | |
| Inosine SCHEMBL16707275 | 1.00 | PAX8 (0.69) | PAX8P2RX3HPGDTYMPMAPK1 | |
| Inosine SCHEMBL13012212 | 1.00 | PAX8 (0.69) | PAX8P2RX3HPGDTYMPMAPK1 | |
| Inosine SCHEMBL10001664 | 1.00 | PAX8 (0.69) | PAX8P2RX3HPGDTYMPMAPK1 | |
| Inosine SCHEMBL29669658 | 1.00 | PAX8 (0.69) | PAX8P2RX3HPGDTYMPMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 897 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739310-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) INHIBITOR COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-05-13 | — | — | EP | claimed |
| US-20250223292-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2025-07-10 | — | — | US | claimed |
| US-20250129163-A1 | PHARMACEUTICAL COMPOSITION AND USE THEREOF | AKESO BIOPHARMA, INC. (CN) | 2025-04-24 | — | — | US | claimed |
| US-20250114450-A1 | PHARMACEUTICAL COMBINATION CONTAINING ANTI-PD-1-ANTI-VEGFA BISPECIFIC ANTIBODY, AND USE THEREOF | AKESO BIOPHARMA, INC. (CN) | 2025-04-10 | — | — | US | claimed |
| CN-119630691-A | Method for treating muscular dystrophy | 萨勒普塔医疗公司 | 2025-03-14 | — | — | CN | claimed |
| EP-4190786-B1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMA (US) | 2025-02-26 | — | — | EP | claimed |
| US-12215355-B2 | Stem cell derived islet differentiation | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-02-04 | — | — | US | claimed |
| WO-2025007955-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) INHIBITOR COMBINATIONS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2025-01-09 | — | — | WO | claimed |
| WO-2024217502-A1 | METHIONINE ADENOSYLTRANSFERASE 2A (MAT2A) INHIBITOR COMBINATIONS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-10-24 | — | — | WO | claimed |
| WO-2024216115-A1 | METHODS FOR PRODUCING A SUPER CENTRAL MEMORY CD8 T CELL SUBTYPE BY POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITION AND USES THEREOF | GEORGETOWN UNIVERSITY (US) | 2024-10-17 | — | — | WO | claimed |
| US-20220233521-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE AND COMBINATION THERAPIES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2022-07-28 | — | — | US | claimed |
| EP-3897204-B1 | FOOD COMPOSITION | UNILEVER IP HOLDINGS B V (NL) | 2022-06-08 | — | — | EP | claimed |
| WO-2022098086-A1 | METHOD FOR DETERMINING SENSITIVITY TO PARP INHIBITOR OR DNA DAMAGING AGENT USING NON-FUNCTIONAL TRANSCRIPTOME | 한국과학기술원 | 2022-05-12 | — | — | WO | claimed |
| US-11311537-B2 | Diagnosis and treatment of lymphoproliferative disorders with PARP inhibitors | UNIVERSITY OF MIAMI (US) | 2022-04-26 | — | — | US | claimed |
| US-11291669-B2 | Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent | KARUS THERAPEUTICS LIMITED (GB) | 2022-04-05 | — | — | US | claimed |
| WO-2022060477-A1 | METHODS FOR TREATING CANCERS WITH INHIBITORS TARGETING THE ROLE OF GRB2 IN DNA REPAIR | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-03-24 | — | — | WO | claimed |
| EP-3966782-A2 | METHODS FOR CHARACTERIZING AND TREATING A CANCER TYPE USING CANCER IMAGES | Tesaro, Inc. (US) | 2022-03-16 | — | — | EP | claimed |
| EP-3534959-B1 | TREATMENT OF LYMPHOPROLIFERATIVE DISORDERS WITH PARP INHIBITORS | UNIV MIAMI (US) | 2022-03-02 | — | — | EP | claimed |
| WO-2022020218-A1 | DIAGNOSTIC METHODS FOR CANCER USING AXL DECOY RECEPTORS | ARAVIVE INC (US) | 2022-01-27 | — | — | WO | claimed |
| US-11229654-B2 | Combination therapy of tetracyclic quinolone analogs for treating cancer | SENHWA BIOSCIENCES, INC. (TW) | 2022-01-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11291669-B2 | Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent | MCL1, MYC, XIAP | PAX8 4276/4885P2RX3 4588/4885HPGD 3469/4885 |
| US-20250223292-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, MAP3K20, CHEK1 | PAX8 4040/4885P2RX3 3286/4885HPGD 3908/4885 |
| US-11229654-B2 | Combination therapy of tetracyclic quinolone analogs for treating cancer | CXCR4, CXCR6, TLR7 | PAX8 582/4885P2RX3 1037/4885HPGD 1583/4885 |
| US-20220233521-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE AND COMBINATION THERAPIES THEREOF | ATR, CHEK1, CHEK2 | PAX8 3636/4885P2RX3 2526/4885HPGD 3658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.